Current disease status-Recurrent cancer - Page 5 of 19 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Looking for patients with advanced non-small cell lung cancer to test the effectiveness of Poziotinib

Looking for patients with advanced non-small cell lung cancer to test the effectiveness of Poziotinib

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...

Read More

Brigatinib for the treatment of previously treated ALK-positive non-small-cell lung cancer

Brigatinib for the treatment of previously treated ALK-positive non-small-cell lung cancer

Posted by on Aug 2, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...

Read More

Can sentinel lymph node biopsy predict outcome in locally recurrent or in-transit melanomas?

Can sentinel lymph node biopsy predict outcome in locally recurrent or in-transit melanomas?

Posted by on Jun 5, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the role of sentinel node biopsy (SLNB) in locally recurrent (LR; when the cancer comes back) melanoma or in-transit (IT; spreads to a lymph vessel before it reaches the nearest lymph node) melanoma. Researchers suggested that SLNB should be performed in these patients. Some background The sentinel lymph node...

Read More

Osimertinib is effective in pretreated non-small cell lung cancer with EGFR-T790M mutations

Osimertinib is effective in pretreated non-small cell lung cancer with EGFR-T790M mutations

Posted by on May 1, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined the effectiveness and safety of osimertinib (Tagrisso) for treating patients with advanced non-small cell lung cancers that harbor T790M mutations. The authors concluded that the drug is promising in both safety and effectiveness at treating this type of cancer. Some background Non-small cell lung cancers...

Read More

Searching for patients with previously treated stage 4 squamous cell lung cancer to test immunotherapies

Posted by on Apr 25, 2017 in Lung cancer | 0 comments

In a nutshell This phase III trial aims to determine whether nivolumab (Opdivo) is effective at treating recurrent stage IV squamous cell lung cancer alone or in combination with ipilimumab (Yervoy). The main outcomes of the trial will be overall survival (time from beginning trial until death), progression free survival (time from beginning trial...

Read More

How effective is metronomic chemotherapy with vinorelbine and capecitabine in patients with advanced HER2-negative breast cancer?

How effective is metronomic chemotherapy with vinorelbine and capecitabine in patients with advanced HER2-negative breast cancer?

Posted by on Apr 3, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated whether metronomic chemotherapy with oral vinorelbine (Navelbine) and capecitabine (Xeloda) was effective in treating patients with advanced HER2-negative breast cancer (BC). This form of treatment was found to be safe and effective for this patients group. Some background Metronomic chemotherapy is a form of...

Read More

How does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer

How does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer

Posted by on Mar 20, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...

Read More

Comparing axillary lymph node ultrasound and fine needle aspiration in breast cancer

Posted by on Mar 4, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated whether patients with a suspicious axillary lymph node (ALN) but negative fine-needle aspiration result (FNA) can be considered as having node-negative disease (AUN). The study concluded that patients with suspicious ALN on ultrasound but negative FNA results can be treated as having node-negative disease. Some...

Read More

Can radiation and hormone therapy after surgery improve prostate cancer survival rates?

Can radiation and hormone therapy after surgery improve prostate cancer survival rates?

Posted by on Jan 21, 2017 in Prostate cancer | 1 comment

In a nutshell The aim of this study was to determine whether radiation therapy in combination with hormonal therapy improved survival in men with prostate cancer that has spread to the lymph nodes after surgery. Researchers concluded that patients treated with radiation therapy and hormone therapy had a significantly higher survival rate compared to...

Read More